Related references
Note: Only part of the references are listed.Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial
Jane C. Burns et al.
LANCET CHILD & ADOLESCENT HEALTH (2021)
Kawasaki Disease: an Update
Eileen Rife et al.
CURRENT RHEUMATOLOGY REPORTS (2020)
Cardiovascular Involvement in Kawasaki Disease Is Much More Than Mere Coronary Arteritis
Rakesh Kumar Pilania et al.
FRONTIERS IN PEDIATRICS (2020)
Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
Zhouping Wang et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2020)
Indirect-comparison meta-analysis of treatment options for patients with refractory Kawasaki disease
Han Chan et al.
BMC PEDIATRICS (2019)
State-of-the-art acute phase management of Kawasaki disease after 2017 scientific statement from the American Heart Association
Yi-Ching Liu et al.
PEDIATRICS AND NEONATOLOGY (2018)
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial
Masaaki Mori et al.
SCIENTIFIC REPORTS (2018)
Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis
Li-Jun Xue et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2017)
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease A Scientific Statement for Health Professionals From the American Heart Association
Brian W. McCrindle et al.
CIRCULATION (2017)
Adjunctive therapies for Kawasaki disease
Anita J. Campbell et al.
JOURNAL OF INFECTION (2016)
Kawasaki Disease
Jane W. Newburger et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
INFLIXIMAB AS THE FIRST RETREATMENT IN PATIENTS WITH KAWASAKI DISEASE RESISTANT TO INITIAL INTRAVENOUS IMMUNOGLOBULIN
Youngmin Youn et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Kawasaki disease: insights into pathogenesis and approaches to treatment
Stanford T. Shulman et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial
Adriana H. Tremoulet et al.
LANCET (2014)
Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Steroid Pulse Therapy for Children With Intravenous Immunoglobulin Therapy-Resistant Kawasaki Disease: A Prospective Study
Masayuki Teraguchi et al.
PEDIATRIC CARDIOLOGY (2013)
Epidemiologic Features of Kawasaki Disease in Japan: Results of the 2009-2010 Nationwide Survey
Yosikazu Nakamura et al.
JOURNAL OF EPIDEMIOLOGY (2012)
Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study
Mary Beth Son et al.
JOURNAL OF PEDIATRICS (2011)
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
Jeroen P. Jansen et al.
VALUE IN HEALTH (2011)
The strategy of immune globulin resistant Kawasaki disease: A comparative study of additional immune globulin and steroid pulse therapy
Shohei Ogata et al.
JOURNAL OF CARDIOLOGY (2009)
Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin
Masaru Miura et al.
EUROPEAN JOURNAL OF PEDIATRICS (2008)
Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease
T. Furukawa et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2008)
Share Paper
